BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals Inc. (VGX), a leading developer of DNA vaccines and therapies for infectious diseases and cancer, announced today preclinical results indicating that its avian influenza DNA vaccine delivered using intramuscular or intradermal electroporation provided 100% protection of non-human primates against the H5N1 avian influenza virus. The vaccine also provided protection against multiple unmatched avian influenza strains. The data was published in the Journal of Virology in a paper titled, “Electroporation of Synthetic DNA Antigens Offers Protection in Non-Human Primates Challenged with Highly Pathogenic Avian Influenza.” The results support advancing this DNA vaccine candidate into human clinical studies.
